MYMD
MyMD Pharmaceuticals, Inc. [MYMD] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MYMD Stock Summary
In the News
MYMD Financial details
Company Rating
-
Market Cap
5.18M
Income
-2.92M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
6
Optionable
No
Shortable
Yes
Earnings
29 Mar 2024
P/E
-2.2
Forward P/E
-
PEG
0.29
P/S
-
P/B
0.58
P/C
-
P/FCF
-0.8
Quick Ratio
1.49
Current Ratio
1.71
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.92
EPS next Y
-
EPS next Q
-
EPS this Y
-77.83%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-63.14%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-173.58%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-19%
ROE
-31%
ROC
-0.99%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-8%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.07-70.5
52W High
-
52W Low
-
RSI
50
Rel Volume
0.1
Avg Volume
229.43K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
3.171
-
-
Volatility
0.02%, 0.02%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 229.43K
- Market Capitalization 5.18M
- Employee 6
- CEO Dr. Christopher C. Chapman Jr., M.D.
- Headquarters Baltimore,MD,US
- IPO Date 2014-01-23
-
Website
https://www.mymd.com 
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
